However, the combination of markers, as CHGA/PP, CHGA/NSE, GLUT-1/Ki-67 have been shown to increase specificity and sensitivity, to trace back to the primary tumor site and to better assess the disease aggressiveness, thus helping clinicians in therapeutic decisions. Here, SLC2A1 is linked to neoplasm.